Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Genetic Technologies Announced New Publication Highlights geneType's ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification
BENZINGA 3:41 PM ET 2/8/2023
People don’t realize how big a deal this is yet
Company like exact science will take this little guy out. Should be a good payout or share swap
https://stockcharts.com/h-sc/ui?s=gene&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/gene/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100
https://www.barchart.com/stocks/quotes/gene/opinion
Open gap @ $1.01 to close!
MM’s getting ready to unleash back up soon.
Exact science colon cancer monitoring stock off the chart this one will follow.
Yep, patience with this one. Hold an wait on money you do not need. $$$
This stock has went to 10 and 8 dollars in a day I guess that is what we are waiting on
GENE: Indeed!! (My only concern here is that WOMEN'S issues normally get little respect behind anything & anybody on 'Wall Street'. Today, for example Peeps are chasing this morning @RSLS, merely behind their FLUFF news about how they just got their SHARES COUNT straightened-out; how WONDERFUL!!)
This could be a blockbuster! Aside from all others, what their science could produce is endless! $$$$
GENE: Hey, Admiral H-C, it's about time that Global Medical Science gets SERIOUS about these insidious Women's diseases. (We Men have OUR issues too, but when Ladies have to get those body parts cut-off or cut-out, it can devastate their own lives, their families, inter alia; GET SERIOUS ABOUT THIS, Planet Earth!! Just like this GENE Firm is desperately TRYING to do. GO-GO-GO-GENE!!!!!!)
WOMEN'S HEALTH MATTERS!!!!!!
This is serious science ahead, take it how you want to
Agree, we loaded an loaded an loaded an not dumping
GENE: All bullshit aside, Ladies' BREAST & OVARIAN CANCER just might be taken SERIOUSLY today in the good old United States of HYPOCRISY --- thanks to THIS little Company!!
https://www.globenewswire.com/news-release/2023/02/03/2601298/0/en/GENE-to-Launch-World-s-First-Comprehensive-Risk-Test-for-Breast-Ovarian-Cancer.html
Interesting open coming, millys were bought over the 2.65-3+
GENE I had sold all and canceled all my orders was just going to post they havent raised money in a year and just told my buddy on the phone before the offering came out, that they put 2 PR's back to back probably to pump the price then make an offering
https://finance.yahoo.com/news/genetic-technologies-announces-6-56-163000086.html
I didn't want to post my negative thoughts but, my gut was spot on!!!
That news was telling. Missed it.
Great job!
GENE
mb
3.25!!!!
already back to $3
7am could push it either way
lets see
Its like clockwork, always
GENE 2.56 lets see make new highs, before theycrash and burn it like all the rest...
Now $3.00
GENE wow 2.28
1.10 from 1.62 pm hi
* * $GENE Video Chart 04-09-2021 * *
Link to Video - click here to watch the technical chart video
Simon Morriss, CEO of Genetic Technologies, stated: ‘We are excited to be partnering with IBX, to enable our COVID-19 Risk Test to be introduced commercially into the COVID-19 product landscape in the US. This agreement is a significant milestone for GTG representing the first multi-year commercial agreement the Company has entered into for the sale and distribution of one of its developed products.
“Our COVID-19 Risk Test is designed to provide individuals with the ability to understand their personal risk associated with contracting a serious case of this disease. Alongside existing treatment options and vaccines, we believe this test will enable more insightful decisions for states, workplaces and individuals on pathways forward in managing this pandemic.”
IBX is a market-disrupting central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas.
https://ibx.bio/
IBX launched its SARS-CoV-2 saliva-test in May 2020, after receiving FDA Emergency Use Authorization. It was the first test to utilise saliva as the primary biomaterial for SARS-CoV-2, and IBX subsequently became the first company to offer an at-home collection with this approach.
Robin Grimwood, IBX Chief Executive Officer, stated: “We view this initial agreement for the sale and distribution of Genetic Technologies’ COVID-19 Risk Test as a critical collaboration in line with our mission to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and, eventually, cures for these diseases. We are uniquely and strategically positioned with our partners to deliver the COVID-19 Risk Test and provide remote telehealth services and reporting, utilising our extensive array capability and capacity across a number of platforms. We were proud to offer the first COVID-19 PCR saliva test last spring and now see the COVID-19 Risk Test as an important next step with providing patients with the information they need to make the best decisions possible for their own health, their family’s health and the health of their community.”
The GTG team are in final stages to submit the COVID-19 Risk Test for clearance from Clinical Laboratory Improvement Amendments (CLIA) and will update the market as and when clearance is received.
GTG signs 3-year US co-exclusive licence agreement for COVID risk test
https://ausstocks.com.au/wp-content/uploads/austocks/gtg/2021_03_03_GTG_c126461283f9282d1258b9c1981a6834.pdf
Were getting close. Need to break 5.40 I think to really get some speed and push into the 6 range. Lets see how the day goes. Would be nice for some news anytime now.
I hope you are correct. ;)
As you say, time will tell.
Message in reply to:
Watching the trading. Dips and buys. IMHO if the market holds up I think this may be the week. Watch for it to go above 5.40 if that is taken out 6 is probable in the cards. Especially if we have news.. Then maybe even 7 or higher. Of course it may take another week or 2 but its getting close.
Time Will Tell
Watching the trading. Dips and buys. IMHO if the market holds up I think this may be the week. Watch for it to go above 5.40 if that is taken out 6 is probable in the cards. Especially if we have news.. Then maybe even 7 or higher. Of course it may take another week or 2 but its getting close.
Time Will Tell
What makes you think so?
I'm only holding a small amount until I learn more. Still haven't had time to research due to traveling. Home now and may start serious research in a few days.
Message in reply to:
This week for Gene 2-15-21 I am looking for a push higher this week. I think we get near or over 6. Lets see if we get some new to make this happen.
Followers
|
62
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2536
|
Created
|
04/05/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/h?s=GENE
http://brevagen.com/
http://phenogensciences.com/c/breast-cancer-risk-assessment-overview
Genetic Technologies is a leading-edge molecular testing business with over 20 years experience globally. The Company specialises in providing an extensive portfolio of genetic tests, including those addressing various aspects of cancer development, progression and management.
Genetic Technologies is the only genetic testing company with testing options directed at both familial and non-familial breast cancer. We provide accurate and rapid turnaround times with the choice of express testing options. Genetic Technologies’ molecular tests provide personalised and actionable diagnostic results to patients and clinicians enabling them to make better informed choices and access to intervention strategies.
Listed on the ASX (GTG) and NASDAQ (GENE), Genetic Technologies has created a successful multi-faceted genetic testing business together with expertise in the intellectual property field. The Company partners with world leading suppliers, clinical researchers and academic collaborators.
Following the acquisition of BREVAGen™, a proprietary breast cancer risk assessment test, Genetic Technologies has established operations in the US (Phenogen Sciences, Inc., a US division of Australia-based Genetic Technologies Limited) enabling us to offer this exciting test in all 50 states.
Gallery View 4: (Full Sto, MACD, Aroon8)
>
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |